Table 2.
Response and survival outcomes (n = 29 patients)
| Best response ≥ MR | 16 (55%, 95% CI 36–74) |
| Best response categories | |
| Very good partial response (VGPR) | 3 (10%) |
| Partial response (PR) | 6 (21%) |
| Minor response (MR) | 7 (24%) |
| Stable disease (SD) | 4 (14%) |
| Progressive disease (PD) | 7 (24%) |
| Not evaluable | 2 (7%) |
| Best response ≥ MR by subgroup | |
| High-risk cytogenetics (n = 9) | 7 (78%) |
| VGPR | 1 |
| PR | 2 |
| MR | 4 |
| Lenalidomide + bortezomib; double-refractory (n = 10) | 4 (40%) |
| VGPR | 1 |
| PR | 1 |
| MR | 2 |
| Duration of response (months) (n = 16) | 4.0 (1.8–5.7) |
| Overall survival (OS), median (95% CI) (months) | 21.6 (13.0–50.1) |
| 6-month OS rate | 82% (62–92) |
| 12-month OS rate | 79% (58–90) |
| 18-month OS rate | 59% (38–75) |
| 24-month OS rate | 45% 25–63) |
| Time to progression, median (95% CI) (months) | 3.6 (2.0–5.1) |
| Progression-free survival (PFS), median (95% CI) (months) | 3.4 (2.0–4.9) |
| 4-month PFS rate | 43% (25–60) |
| 6-month PFS rate | 20% (7–36) |
| 12-month PFS rate | 8% (1–22) |
Data are shown as n (%), median (95% CI) or % (95% CI) unless otherwise indicated. Median follow-up 24.9 months